Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Sunovion Pharmaceuticals, formerly Separacor

Organization & Developments: Sunovion

Parents

2019: FDA Rejects Sunovion Pharmaceutical’s Parkinson’s Disease Treatment
2020: FDA Gives Thumbs-Up to Sunovion's Under-the-Tongue Parkinson's Drug
And a Number of Inhalant Drugs for Treating Asthma
Omnaris, a nasal spray for treating allergy symptoms
Sunovion Pharmaceuticals has announced that the FDA approved its once-daily, oral tablet for treating schizophrenia.(2010)
The drug company has six other FDA-approved drugs, including the insomnia treatment Lunesta
The drug, Latuda (lurasidone HCl), is expected to be available in the U.S. early next year (2010)